🔎 Trials Near Me

Akèy › Sendwòm myelodisplastik › Illinois › Chicago

Etid klinik pou Sendwòm myelodisplastik nan Chicago, IL

13 etid pou Sendwòm myelodisplastik ap chèche patisipan nan sit nan ak bò kote Chicago (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.

Tèks ofisyèl etid la (Anglè)

Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →

Testing the Addition of an IDH2 Inhibitor, Enasidenib, to Usual Treatment (Cedazuridine-Decitabine) for Higher-Risk Myelodysplastic Syndrome (MDS) With IDH2 Mutation (A MyeloMATCH Treatment Trial)

Ap rekriteFaz 2
  • Northwestern University, Chicago
  • Swedish Covenant Hospital, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Laj 18 ak plis · Tout sèks · Mizajou Oct 2, 2026 · NCT06577441

Testing the Anti-cancer Drug, Cirtuvivint, and Its Combination With ASTX727 to Improve Outcomes in Patients With Acute Myeloid Leukemia and Myelodysplastic Syndromes

Ap rekriteFaz 1
  • University of Chicago Comprehensive Cancer Center, Chicago
Laj 18 ak plis · Tout sèks · Mizajou Oct 1, 2026 · NCT06484062

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

Ap rekriteFaz 2
  • Northwestern University, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
  • ak 1 plis
Laj 18 ak plis · Tout sèks · Mizajou Sep 25, 2026 · NCT05564390

Ivosidenib (IVO) Monotherapy and Azacitidine (AZA) Monotherapy in Patients With Hypomethylating Agent (HMA) Naive Myelodysplastic Syndromes (MDS) With an IDH1 Mutation

Ap rekriteFaz 3
  • University of Chicago, Duchossois Center for Advanced Medicine (DCAM), Chicago
Laj 18 ak plis · Tout sèks · Mizajou Sep 3, 2026 · NCT06465953

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

Ap rekriteFaz 1/2
  • Lurie Children's Hospital-Chicago, Chicago
  • University of Illinois, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
Jiska laj 22 · Tout sèks · Mizajou Aug 25, 2026 · NCT04726241

Mosaic Trial for Stem Cell Transplant Recipients

Ap rekrite
  • Northwestern University Feinberg School of Medicine, Chicago
Laj 18 ak plis · Tout sèks · Mizajou Aug 3, 2026 · NCT06960993

A Study of CTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic Syndromes

Ap rekriteFaz 1/2
  • Northwestern University, Chicago
Laj 18 ak plis · Tout sèks · Mizajou Apr 13, 2026 · NCT05732103

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

Ap rekriteFaz 1/2
  • Northwestern, Chicago
Laj 12 ak plis · Tout sèks · Mizajou Mar 24, 2026 · NCT04988555

Venetoclax Basket Trial for High Risk Hematologic Malignancies

Ap rekriteFaz 1
  • Ann & Robert H Lurie Children's Hospital of Chicago, Chicago
Laj 1 a 40 · Tout sèks · Mizajou Mar 12, 2026 · NCT05292664

Leukemia and Lymphoma Society (LLS) Services Impact on Outcomes and Care

Ap rekrite
  • University of Chicago Comprehensive Cancer Center, Chicago
Laj 18 ak plis · Tout sèks · Mizajou Feb 20, 2026 · NCT05745285

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

Ap rekriteEtid obsèvasyon
  • Massive Bio SYNERGY-AI site, Chicago
Tout laj · Tout sèks · Mizajou Oct 28, 2025 · NCT03452774

A Study of BH-30236 in Relapsed/ Refractory Acute Myelogenous Leukemia and Higher Risk Myelodysplastic Syndrome

Ap rekriteFaz 1
  • Northwestern Medicine - Northwestern Memorial Hospital Galter Pavilion, Chicago
Laj 18 ak plis · Tout sèks · Mizajou Sep 24, 2025 · NCT06501196

Etid Sendwòm myelodisplastik nan lòt vil

Lòt etid nan Chicago

Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.